
Preeclampsia Market Report and Forecast 2024-2032
Description
Preeclampsia Market Report and Forecast 2024-2032
Preeclampsia Market Report and Forecast 2024-2032
Preeclampsia Market Outlook
The preeclampsia market size is anticipated to grow at a CAGR of 1.8% during the forecast period of 2024-2032, driven by advancements in early detection and monitoring along with growing hypertension prevalence across major markets.
Preeclampsia: Introduction
Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to organ systems, often the kidneys. It usually occurs after 20 weeks of pregnancy in women whose blood pressure had been normal. Symptoms include persistent headaches, blurred vision, and abdominal pain. Preeclampsia can lead to serious, even fatal, complications for both mother and baby if not properly managed. Treatment often involves medication to lower blood pressure and, when necessary, early delivery of the baby.
Key Trends in the Preeclampsia Market
There's a growing emphasis on early detection of preeclampsia through advanced screening methods. This includes the development of new biomarkers and diagnostic tests that can identify women at high risk earlier in their pregnancies.
There has been increasing research, focusing on preventative measures, such as the use of low-dose aspirin in high-risk women, along with dietary and lifestyle interventions to reduce the incidence of preeclampsia.
Efforts are underway to develop targeted therapies that address the underlying pathophysiology of preeclampsia, aiming to treat the condition more effectively and with fewer side effects.
The use of digital health tools, such as telehealth platforms and remote monitoring devices, is on the rise. These tools assist in closely monitoring blood pressure and other vital signs in pregnant women, especially those at risk of preeclampsia.
There's an increased focus on educating pregnant women about the signs and symptoms of preeclampsia, emphasizing the importance of regular prenatal care and timely reporting of symptoms.
Global collaboration among research institutions, healthcare providers, and pharmaceutical companies is enhancing the development of new treatments and management strategies.
The management of preeclampsia is being increasingly recognized as a critical aspect of global maternal health initiatives, leading to more funding and resources being allocated to address this condition.
Personalized medicine, considering individual risk factors such as genetics, pre-existing conditions, and pregnancy history, is gaining traction in managing preeclampsia.
Preeclampsia Market Segmentation
Market Breakup by Treatment
- Medication to Lower B.P.
- Corticosteroids
- Anticonvulsants Medication
- Mild Preeclampsia
- Severe Preeclampsia
- Hospitals
- Clinics
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
In North America, there is a high level of awareness and advanced healthcare infrastructure, leading to better screening, early detection, and management of preeclampsia. The focus is on integrating new diagnostic methods and treatment protocols. Research and development in this field are also robust, with ongoing clinical trials and studies.
European countries benefit from strong healthcare systems, which facilitate comprehensive prenatal care, including screening and management of preeclampsia. There's a significant focus on research and adherence to established guidelines for preeclampsia management. Some countries in Europe are leaders in developing new diagnostic and treatment methods.
In Japan, a varied approach is seen due to diverse healthcare systems across countries. The management of preeclampsia aligns with global standards, but in many developing countries, challenges such as limited access to prenatal care and low awareness can impact the management of the condition. Efforts are being made to improve prenatal care and education about preeclampsia.
Preeclampsia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific Inc.
- Baxter
- Bayer AG
- Merck & Co., Inc
- F. Hoffmann-La Roche Ltd
- Siemens Healthcare GmbH
- PerkinElmer Inc
- Sera Prognostics
- DRG Instruments GMBH
- Metabolomic Diagnostics
- Diabetomics, Inc.
- Hitachi Ltd
- Cardinal Health Inc
- BioMerieux SA
- Fujirebio Diagnostics
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
180 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Preeclampsia Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Preeclampsia Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2017-2032)
- 5.2 United States Preeclampsia Epidemiology Forecast (2017-2032)
- 5.3 EU-4 and United Kingdom Preeclampsia Epidemiology Forecast (2017-2032)
- 5.3.1 Germany Preeclampsia Epidemiology Forecast (2017-2032)
- 5.3.2 France Preeclampsia Epidemiology Forecast (2017-2032)
- 5.3.3 Italy Preeclampsia Epidemiology Forecast (2017-2032)
- 5.3.4 Spain Preeclampsia Epidemiology Forecast (2017-2032)
- 5.3.5 United Kingdom Preeclampsia Epidemiology Forecast (2017-2032)
- 5.4 Japan Preeclampsia Epidemiology Forecast (2017-2032)
- 6 Preeclampsia Market Overview – 7MM
- 6.1 Preeclampsia Market Historical Value (2017-2023)
- 6.2 Preeclampsia Market Forecast Value (2024-2032)
- 7 Preeclampsia Market Landscape – 7MM
- 7.1 Preeclampsia Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Preeclampsia Product Landscape
- 7.2.1 Analysis by Products
- 7.2.2 Analysis by Indications
- 7.2.3 Analysis by Route of Administration
- 8 Preeclampsia Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Preeclampsia Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Preeclampsia Market Segmentation – 7MM
- 11.1 Preeclampsia Market by Treatment
- 11.1.1 Market Overview
- 11.1.2 Medication to Lower B.P.
- 11.1.3 Corticosteroids
- 11.1.4 Anticonvulsants Medication
- 11.2 Preeclampsia Market by Disease Type
- 11.2.1 Market Overview
- 11.2.2 Mild Preeclampsia
- 11.2.3 Severe Preeclampsia
- 11.3 Preeclampsia Market by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Clinics
- 11.3.4 Others
- 11.4 Preeclampsia Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Preeclampsia Market
- 12.1 Preeclampsia Market Historical Value (2017-2023)
- 12.2 Preeclampsia Market Forecast Value (2024-2032)
- 12.3 Preeclampsia Market by Disease Type
- 12.4 Preeclampsia Market by Treatment Type
- 13 EU-4 and United Kingdom Preeclampsia Market
- 13.1 Preeclampsia Market Historical Value (2017-2023)
- 13.2 Preeclampsia Market Forecast Value (2024-2032)
- 13.3 Germany Preeclampsia Market Overview
- 13.3.1 Preeclampsia Market by Disease Type
- 13.3.2 Preeclampsia Market by Treatment Type
- 13.4 France Preeclampsia Market Overview
- 13.4.1 Preeclampsia Market by Disease Type
- 13.4.2 Preeclampsia Market by Treatment Type
- 13.5 Italy Preeclampsia Market Overview
- 13.5.1 Preeclampsia Market by Disease Type
- 13.5.2 Preeclampsia Market by Treatment Type
- 13.6 Spain Preeclampsia Market Overview
- 13.6.1 Preeclampsia Market by Disease Type
- 13.6.2 Preeclampsia Market by Treatment Type
- 13.7 United Kingdom Preeclampsia Market Overview
- 13.7.1 Preeclampsia Market by Disease Type
- 13.7.2 Preeclampsia Market by Treatment Type
- 14 Japan Preeclampsia Market
- 14.1 Preeclampsia Market Historical Value (2017-2023)
- 14.2 Preeclampsia Market Forecast Value (2024-2032)
- 14.2.1 Preeclampsia Market by Disease Type
- 14.2.2 Preeclampsia Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Thermo Fisher Scientific Inc.
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Baxter
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Bayer AG
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Merck & Co., Inc
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 F. Hoffmann-La Roche Ltd
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 Siemens Healthcare GmbH
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 PerkinElmer Inc
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 Sera Prognostics
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 DRG Instruments GMBH
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 Metabolomic Diagnostics
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Diabetomics, Inc.
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 Hitachi Ltd
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Cardinal Health Inc
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 BioMerieux SA
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 Fujirebio Diagnostics
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 21 Preeclampsia Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.